NTRK3 and neoplasm: Oral altiratinib (15 mg/kg) treatment of NIH3T3 ETV6-NTRK3 tumors in a subcutaneous murine allograft model abrogated tumor growth, with the expansion of growth upon treatment withdrawal (Supplementary Fig. 2a).